Incyte (INCY) Share-based Compensation Growth (3y) (2013 - 2026)
Analysis
Incyte (INCY) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 17.49% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 9.95% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 4.55% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 30.98% |
| 10 | Incyte | 25.57 Bn | 21.03 Bn | 1.57 Bn | 7.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.25% |
| Mar 31, 2026 | 6.31% |
| Dec 31, 2025 | 5.67% |
| Sep 30, 2025 | 10.70% |
| Jun 30, 2025 | 11.59% |
| Mar 31, 2025 | 11.63% |
| Dec 31, 2024 | 14.15% |
| Sep 30, 2024 | 22.20% |
| Jun 30, 2024 | 8.13% |
| Mar 31, 2024 | 43.98% |
| Dec 31, 2023 | 9.85% |
| Sep 30, 2023 | 3.10% |
| Jun 30, 2023 | 5.60% |
| Mar 31, 2023 | 53.99% |
| Dec 31, 2022 | 7.84% |
| Sep 30, 2022 | 1.52% |
| Jun 30, 2022 | 4.63% |
| Mar 31, 2022 | 41.48% |
| Dec 31, 2021 | 8.87% |
| Sep 30, 2021 | 3.96% |